Sign in Subscribe
United States. Securities and Exchange Commission

Agile Therapeutics Announces 2021 Annual Meeting Results

Strategic Insights

— 1 min read

At the 2021 annual meeting of stockholders of Agile Therapeutics, Inc. held on June 8, 2021, three proposals were submitted to the stockholders for a vote. The proposals included the election of directors, approval of the 2020 compensation of named executive officers, and ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm. A total of 58,572,042 shares, or approximately 66.36% of the total shares entitled to vote, were represented at the meeting, constituting a quorum.

Key Takeaways:

  • Proposal 1: The election of three directors, Al Altomari, John Hubbard, Ph.D., FCP, and James P. Tursi, M.D., was approved with a majority of votes, with Director Altomari receiving the highest number of votes (29,981,617).
  • Proposal 2: The 2020 compensation of named executive officers was approved, with 27,604,992 votes in favor and 5,461,050 votes against.
  • Proposal 3: The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2021 was ratified, with 56,501,992 votes in favor and 1,848,323 votes against.
  • Approximately 66.36% of shares entitled to vote were represented at the meeting, with 25,158,426 broker non-votes.
  • The votes were as follows: Proposal 1 (election of directors): Al Altomari (29,981,617), John Hubbard, Ph.D., FCP (30,205,062), and James P. Tursi, M.D. (30,140,825); Proposal 2 (2020 executive compensation): 27,604,992 versus 5,461,050; Proposal 3 (Ernst & Young LLP appointment): 56,501,992 versus 1,848,323.

Statistics:

  • 58,572,042 shares, or approximately 66.36% of the total shares entitled to vote, were represented at the meeting.
  • 25,158,426 broker non-votes were cast.
  • Director Al Altomari received the highest number of votes (29,981,617) in Proposal 1.

Sources:

  • Agile Therapeutics, Inc. (2021, June 8). FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549.

Read more